Veru plans to initiate a 200-patient Phase 2b study of enobosarm as an add-on to GLP-1 receptor agonists in older adults with obesity, with first patient in expected in the first quarter of 2026 and an interim analysis in the first quarter of 2027. The double-blind, placebo-controlled Plateau trial will test 3 mg enobosarm in patients aged 65 and older with BMI of at least 35 who are starting GLP-1 therapy, targeting percent change in total body weight at 68 weeks as the primary endpoint. Secondary measures include DEXA-based body composition, stair-climb performance, bone mineral density, and patient-reported physical function, alongside metabolic markers. The move follows a prior Phase 2b study in 168 older patients on semaglutide that reported preservation of lean mass and function with enobosarm plus semaglutide and a greater reduction in fat mass over 16 weeks, with weight loss reported as similar across arms in that timeframe. Veru will discuss the broader business update during its February 11 earnings call.
The strategic bet is clear: the next wave of obesity care will not be decided solely on the scale. As GLP-1s redefine weight loss, differential value is migrating to body composition, function, and durability. Positioning a selective androgen receptor modulator as a companion to GLP-1 therapy aims to address two emerging pain points—sarcopenic risk and weight-loss plateaus—particularly in older patients where muscle preservation, bone health, and fall risk carry clinical and economic weight. The design choice to power a 68-week endpoint and to anchor interim analyses on changes in fat and lean mass signals an intent to convert body-composition biology into payer-relevant evidence rather than a mechanistic curiosity.
For patients and HCPs, the promise is a higher-quality weight loss trajectory that preserves mobility and independence. For payers, the bar will be higher: additive cost must be justified by incremental and durable weight loss, fewer adverse consequences of muscle loss, and measurable functional gains that translate into avoided utilization. Including bone mineral density, functional performance, and PROs is a pragmatic nod to those thresholds, but real-world translatability will matter, given the practicalities of DEXA access, adherence to multi-drug regimens, and monitoring in older populations. Regulators have historically focused on percent weight change, so any label predicated on body composition may still need clear superiority on weight and clinically meaningful functional benefit to unlock coverage at scale.
Competitively, the clock is ticking. By the time interim data emerge, GLP-1 combinations and successors—amylin co-agonists, GIP/GLP-1 doublets, GLP-1/glucagon triplets, and long-acting once-weekly or oral entrants—will be further along, many with integrated efficacy and potential cardiometabolic benefit. An oral add-on that improves lean mass retention could carve out a defensible niche in older or frail patients, but commercial viability will hinge on crisp evidence of incremental weight loss and functional outcomes, a clean safety profile across sexes, and alignment with the workflows of endocrinology and primary care. The company’s parallel work with sabizabulin in chronic inflammation related to atherosclerotic cardiovascular disease underscores a broader pivot to cardiometabolic disease, which could become a narrative advantage if the portfolio ties back to cardiovascular risk reduction.
The next strategic question is whether body composition and function become table-stakes endpoints for obesity combinations—and if so, who funds and owns that narrative. If enobosarm can show a clinically meaningful delta on both weight and function while mitigating GLP-1–associated lean mass loss, it could catalyze new partnering models with GLP-1 franchise leaders. If not, payers may view it as a costly adjunct in a market racing toward built-in, multi-pathway agonism.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
